Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
An. acad. bras. ciênc ; 71(2): 265-71, jun. 1999.
Artículo en Inglés | LILACS | ID: lil-234516

RESUMEN

In addition to original research, Far-Manguinhos, the Pharmaceutical Division of the Brazilian Ministry of Healthïs Oswaldo Cruz Foundation (FIOCRUZ), devotes major attention to the finalising of products for use in public health campaigns or, under contract, for private industrial development. Emphasis is on standardisation, adequate supply, safety in use and efficacy. Among the products discussed in this summary of some of its activities in the chemical and pharmaceutical fields are medicinal plants Bidens pilosa, Cymbopogon citratus, Copaifera species, mentha crispa, Phyllanthus tenellus Roxb, and other Physllanthus species, insecticidal plants, Lonchocarpus urucu and Quassia amara, and the insect antifeedant plants Carapa guianensis and Peterodon emarginatus.


Asunto(s)
Academias e Institutos , Fundaciones , Repelentes de Insectos , Insecticidas , Plantas Medicinales , Tecnología Farmacéutica , Medicina de Hierbas
2.
Ciênc. cult. (Säo Paulo) ; 49(5/6): 339-44, Sept.-Dec. 1997. tab, graf
Artículo en Inglés | LILACS | ID: lil-214094

RESUMEN

Medicinal plants are widely employed in both rural and urban Brazil, many in accordance with traditional practices that were developed by the native population or were brought to the country by immigrant peoples from Europe, Africa and Asia. Their use in official public health care requires however more than traditional knowledge. Recently published laws which will come into force by the end of the century, require that scientific evidence be brought to support the popular use, that possible toxicity, especially when chronic use is contemplated, be known to the medical profession and that the raw plant material and final formulation have a chemical composition that lies within limits that can be specific and checked by analysis. Clinical evidence of efficacy should be provided and wherever possible some indication of the mechanism of action and what components of the original plant contribute to this action, are desirable. At the same time, once a plant of given chemical compositon is approved for use, then its widespread production must be organized in such a way that suppy of a product of established quality meets the demand.


Asunto(s)
Humanos , Aprobación de Drogas/legislación & jurisprudencia , Extractos Vegetales/farmacología , Plantas Medicinales/uso terapéutico , Salud Pública , Brasil , Medicina Tradicional China , Extractos Vegetales/farmacocinética , Extractos Vegetales/uso terapéutico , Plantas Medicinales/envenenamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA